Intravitreal Injection of Bevacizumab (Avastin) as Adjunctive Treatment of Proliferative Diabetic Retinopathy - 18/08/11
, Peter A. Nixon, MD a, b, Milton F. White, MD a, b
Inquiries to John O. Mason, III, MD, Retina Consultants of Alabama, 700 South 18th Street, Suite 707, Birmingham, AL 35233Résumé |
Purpose |
To report the use of intravitreal bevacizumab (Avastin) as an adjunctive treatment for proliferative diabetic retinopathy (PDR).
Design |
Retrospective case review.
Methods |
Institutional review board approval to review patient data was obtained for this retrospective study. Three patients underwent intravitreal injection of bevacizumab as part of their treatment for PDR after informed consent was signed. Each patient also underwent fundus photographs before the bevacizumab injection and then one to three weeks after.
Results |
All three patients showed complete regression of their neovascularization elsewhere (NVE) and neovascularization of the disk (NVD) between one and three weeks after injection.
Conclusions |
The speed and degree of neovascular regression after the injection of intravitreal bevacizumab may make this procedure an important adjunctive treatment in the management of selected cases with severe PDR.
Le texte complet de cet article est disponible en PDF.Plan
| Support provided by Research to Prevent Blindness, New York, New York. |
Vol 142 - N° 4
P. 685-688 - octobre 2006 Retour au numéro
Article précédent
- Progression of Choroidal Neovascularization Following Injection of Pegaptanib Sodium (Macugen) in Two Eyes With Neovascular Age-related Macular Degeneration
- Adrienne J. Williams, Sharon Fekrat
- Retinal Vascular Abnormalities and Prevalence of Age-related Macular Degeneration in Adult Chinese: The Beijing Eye Study
- Liang Xu, Shuang Wang, Yibin Li, Jost B. Jonas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?